Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.
Dieses von der Gebert Rüf Stiftung geförderte Projekt wird von folgenden weiteren Projektpartnern mitgetragen:
Förderbeitrag: CHF 150'000
Dauer: 07.2021 - 06.2022
InnoBooster, seit 2018
PD Dr. Cristina Rossi
University Hospital Zurich
Institute of diagnostic and interventional radiology
8091 Zürich (Schweiz)
- cristina.rossi@usz. ch
Catching breast cancer at an early stage can save thousands of women every year. Early diagnosis of breast cancer requires profound understanding of the diagnostic procedures and of the pathological features. However, most of the hospitals cannot afford the employment of the few breast specialists on the market and are exposed to high risks of malpractice and to unnecessary costs. Healthcare providers are calling for a technological shift allowing a more efficient and accurate diagnosis of breast cancer.
b-rayZ has developed a ground-breaking platform based on cutting-edge Artificial Intelligence (AI) for flawless and sustainable breast cancer diagnostics. The platform, perfectly aligned with international requirements and the clinical workflow, hosts a portfolio of software products for the evaluation of breast diagnostic imaging to decrease false positive and negative findings. With the InnoBooster grant, we want to address one main factor hindering the adoption of AI solutions at the customer’s site, i.e. the possibility of performing a “calibration” of the AI outputs with the procedures of the client.
With this project, we want to enable a lean interaction of the customers with the AI algorithms for a traceable decision-making and for easier integration into each clinical workflow. We will leverage the experience of the few specialists in the world to make the best care available to every patient, everywhere. This is a fundamental step for the further consolidation of our products, already certified as medical devices and available on the market. A close cooperation with main breast imaging centers in Switzerland and Norway will allow the evaluation of the new prototype in different clinical settings. The project will strength the synergies already existing with academic and industry partners with an overall financial dimension of over 900’000 CHF.
Am Projekt beteiligte Personen
Letzte Aktualisierung dieser Projektdarstellung 02.06.2021